, 2013 In the past a lot of different biomolecular therapeutics were developed. A common problem using small molecules in therapy is their reduced serum concentration after short time period. The human body clears therapeutic molecules which have a size beneath the kidney clearance threshold in minutes to hours.
openaire +2 more sources
Transplacental Antibody Transfer: Mechanisms, Pregnancy-Related Disruptions, and Emerging Experimental Models. [PDF]
Antibodies (Basel)Li Q +5 more
europepmc +1 more source
Precision Immunomodulation in Pregnancy - Lessons from Nipocalimab. [PDF]
NEJM EvidEke AC.
europepmc +1 more source
Recombinant Human IgG1-Hexamer Reduces Pathogenic Autoantibodies in the K/BxN Mouse Model of Arthritis Independent of FcRn. [PDF]
Int J Mol SciLewis BJB +8 more
europepmc +1 more source
Current status and challenges of biologic targeted therapy for myasthenia gravis in China. [PDF]
Intractable Rare Dis ResGu S, Zhao C.
europepmc +1 more source
Does a Polycistronic 2A Design Enable Functional FcRn Production for Antibody Pharmacokinetic Studies? [PDF]
PharmaceuticsNesmeyanova VS +6 more
europepmc +1 more source
A modular "Catch-and-Play" platform for rapid T-cell engager target assembly for personalised cancer treatment. [PDF]
Signal Transduct Target TherXi X +4 more
europepmc +1 more source
Quantitative Prediction of Human Pharmacokinetics for Fc-Engineered Therapeutic Monoclonal Antibodies With Increased FcRn Binding Mutations After Subcutaneous Injection. [PDF]
Clin Transl SciHaraya K, Kuramochi T.
europepmc +1 more source